Important note
This AI stock analysis for Organigram is not up to date. Creating and accessing our AI stock Analysis (powered by our data and Chat GPT) is only available for our premium users. Sign up to get access today!
Organigram - AI Stock Analysis
Analysis generated July 30, 2025
Organigram Holdings Inc. is a leading licensed producer of cannabis and cannabis-derived products. The company operates in the medicinal and recreational marijuana markets with an array of products that include dried flower, cannabis oils, and extracts. With a strong presence in Canada, Organigram continues to invest in innovation and operational efficiencies to drive growth and capture market share in this competitive space.
Fundamental Analysis
Organigram’s financial health showcases a strong trajectory of growth based on the latest revenue, income, and EBITDA figures.
Revenue: For the last quarter, Organigram reported a revenue of $66 million. This marks an impressive increase of 53.52% compared to the previous quarter, indicating rapid short-term growth. Year-over-year, the revenue surged by 74.34%, reflecting solid and consistent long-term growth.
Net Income: The net income for the last quarter was an encouraging $42 million, representing a staggering 284.94% increase quarter-over-quarter. Compared to the same quarter last year, this figure saw an increase of 256.81%. These numbers indicate a robust improvement in profitability.
EBITDA: The EBITDA stood at $2.7 million, showing a growth of 19.63% from the previous quarter and an impressive year-over-year increase of 77.17%. This indicates that the core earnings of the company are growing steadily.
P/E Ratio: The current P/E ratio is 12.33. This value falls within a normal range and suggests that the stock is neither overvalued nor undervalued, providing a balanced outlook on the stock’s valuation.
Technical Analysis
The technical perspective offers mixed signals for Organigram’s stock.
Current Stock Price: The stock is currently priced at $1.41, which is a 4.44% increase compared to a month ago, indicating a positive short-term trend. However, over the longer period of a year, the stock price has declined by 16.07%, raising potential concerns about long-term performance.
The trend currently shows bearish tendencies. The SMA10 is currently 1.50, which, being lower than the previous SMA10, suggests a downward trend in price movement. Meanwhile, the RSI stands at 61, indicating neutral conditions, which means the stock is neither overbought nor oversold.
Alternative Data Analysis
Analyzing the alternative data sheds light on Organigram’s operational and market dynamics.
Job Postings & Employee Sentiment: The company has 16 open positions, up by 167% over the last few months, indicating plans for expansion and growth. Employee sentiment toward the business outlook is neutral, suggesting a cautiously optimistic workforce.
Customer Acquisition: The company’s webpage has about 11,000 visitors, but recent months have seen a 45% drop in visitors, which could imply challenges in attracting or retaining customers.
Customer Engagement: AltIndex's AI score for Organigram is 53, which is interpreted as a hold signal. This AI score reflects a neutral stance based on a combination of fundamental, technical, and alternative data indicators.
Conclusion and Recommendation
Organigram shows strong fundamental growth with notable increases in revenue, net income, and EBITDA. However, the stock exhibits a mixed technical outlook with a recent positive short-term trend but concerning long-term bearish signals. Additionally, alternative data presents a balance between growth ambitions and potential challenges in customer acquisition and engagement. Given these varied factors, the stock is best approached with cautious optimism, and initiating or holding a position could be considered while closely monitoring future performance indicators.
Disclaimer: This AI stock analysis, generated by an experimental AI tool, is for informational purposes only and not financial advice. Information is based on publicly available data and may not always be accurate or current.
